Sweat Chloride Testing and Nasal Potential Difference (NPD) Are Primary Outcome Parameters in Treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Journal of Personalized Medicine Année : 2021

Sweat Chloride Testing and Nasal Potential Difference (NPD) Are Primary Outcome Parameters in Treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators

Résumé

With the advent of CFTR modulators, surrogate outcome parameters that accurately quantify the improvement in CFTR activity are needed. In vivo biomarkers that reflect CFTR ion transport and can serve as outcomes in the treatment of CFTR modulators are the sweat Cl− test (SCT), the nasal potential difference (NPD) measurement or the intestinal current measurement (ICM). This review focus on the SCT and NPD. The SCT displays a low intra-patient variability in contrast to the NPD. It has been used extensively as a biomarker of CFTR function in clinical trials of CFTR modulator therapies and provides evidence for change in the short term. The level of functional rescue in the NPD increases up to 40% of normal CFTR in patients with a Gly551Asp treated with ivacaftor monotherapy, while in F508del homozygous patients treated with ivacaftor-lumacaftor, activity increased on average up to ~20% of normal activity. While both tests provide evidence of the effect on CFTR activity, they cannot be used at an individual level to predict the response to any CFTR modulators. Nevertheless, their rapid modification, reflecting electrophysiological properties, highlight their potential use in proof-of-concept studies for CFTR modulators.
Fichier principal
Vignette du fichier
jpm-11-00729-v2(1).pdf (834.21 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03351293 , version 1 (22-09-2021)

Identifiants

Citer

Isabelle Sermet-Gaudelus, Thao Nguyen-Khoa, Aurélie Hatton, Kate Hayes, Iwona Pranke. Sweat Chloride Testing and Nasal Potential Difference (NPD) Are Primary Outcome Parameters in Treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. Journal of Personalized Medicine, 2021, 11 (8), pp.729. ⟨10.3390/jpm11080729⟩. ⟨hal-03351293⟩
5 Consultations
16 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More